# Semax: A Research Digest of the Heptapeptide Literature

> Semax is a synthetic heptapeptide derived from ACTH(4-10), studied for neuroprotection, BDNF upregulation, and cognitive performance in rodent models. An indexed digest of the published research record.

## What the Semax literature has documented

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone, specifically positions 4 through 10. [1] It does not carry the steroidogenic activity of full ACTH. The compound has been studied in rodent ischemia models, in vitro cell culture systems, behavioral paradigms, and a limited body of Eastern European observational clinical work.

The research literature on Semax is predominantly Russian in origin, produced at the Institute of Molecular Genetics of the Russian Academy of Sciences and affiliated institutions across four decades. That provenance matters: it means the compound has been studied rigorously in one scientific tradition, while independent Western replication in randomized controlled trials remains sparse. Both facts belong in the same sentence.

The headline mechanistic findings are well-replicated within the Russian literature: Semax binds melanocortin receptor MC4R with nanomolar affinity, upregulates BDNF and NGF mRNA rapidly in hippocampal and glial cells, and inhibits enkephalin-degrading serum enzymes. [1][2][7][10] A single intranasal dose of 50 µg/kg produced a 3-fold increase in BDNF mRNA in rat hippocampus within hours. [2] Eight-fold elevation of BDNF mRNA was observed in rat basal forebrain glial cultures within 30 minutes. [7]

Registration and approval context: Semax has been approved as a pharmaceutical drug in Russia since 1994 for cerebrovascular indications, cognitive disorders, and optic neuropathy. It is not approved by the FDA or EMA for any indication. It is unscheduled as a controlled substance in the United States as of 2025.

## What Is Semax Used For in Research?

The Semax research literature clusters around five primary investigative domains.

**Cerebral ischemia and stroke recovery.** The largest body of work places Semax in rat middle cerebral artery occlusion models, where it consistently suppresses neuroinflammatory gene cascades and promotes expression of neurotrophic and vascular genes. [4][5][6]

**BDNF and neurotrophin modulation.** Multiple studies document rapid, dose-dependent upregulation of BDNF mRNA and protein in hippocampal, cortical, and glial cells. [1][2][7][8] TrkB phosphorylation increases in parallel. [2]

**Cognitive performance in rodent models.** Semax-treated rats show improved conditioned avoidance reactions consistent with enhanced learning. [2] Dopaminergic and serotonergic modulation in the striatum underlies proposed attention and memory effects. [3]

**Anxiolytic and antidepressant-like effects.** In chronic unpredictable stress models, Semax reversed anhedonia, body-weight suppression, adrenal hypertrophy, and decreased hippocampal BDNF. [16]

**Neuroprotection in injury models.** The 2025 spinal cord injury study documents functional recovery improvement via a mu-opioid receptor / USP18 deubiquitination axis. [21]

## Why is Semax studied?

Researchers study Semax for its potential neuroprotective, nootropic, and anxiolytic properties in rodent models — particularly in stroke recovery, BDNF upregulation, and cognitive task performance. [1][2][4] The compound's dual mechanism — melanocortin receptor binding plus enkephalinase inhibition — gives it a pharmacological profile distinct from either classical nootropics or peptide growth factors. [10]

## What does Semax do?

In animal and in vitro models, Semax modulates BDNF expression, inhibits nitric oxide synthesis, and activates dopamine and serotonin signaling pathways associated with attention and memory consolidation. [1][2][3] At the receptor level, Semax binds MC4R with a dissociation constant (KD) of approximately 2.4 ± 1.0 nM in rat forebrain membranes. [1]

## Recent studies (2024-2025)

Four peer-reviewed publications in 2024 and 2025 extended the Semax literature into new mechanistic territory: antidepressant-like effects in chronic stress models [16], copper chelation from amyloid-beta complexes [20], spinal cord injury recovery via Oprm1/USP18/FTO deubiquitination [21], and region-specific hippocampal calcium signaling [19].

## References

[1] Dolotov OV, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry. 2006. DOI: 10.1111/j.1471-4159.2006.03658.x — https://pubmed.ncbi.nlm.nih.gov/16635254/
[2] Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006. DOI: 10.1016/j.brainres.2006.07.108 — https://pubmed.ncbi.nlm.nih.gov/16996037/
[3] Inozemtseva LS, et al. Semax activates dopaminergic and serotoninergic brain systems in rodents. Neuroscience Letters. 2006. DOI: 10.1016/j.neulet.2005.11.047 — https://pubmed.ncbi.nlm.nih.gov/16362768/
[4] Sudarkina OY, et al. Brain Protein Expression Profile Confirms the Protective Effect of Semax in a Rat Model of Cerebral Ischemia-Reperfusion. IJMS. 2021. DOI: 10.3390/ijms22126179 — https://pubmed.ncbi.nlm.nih.gov/34201112/
[5] Medvedeva EV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia. BMC Genomics. 2014. — https://pmc.ncbi.nlm.nih.gov/articles/PMC3987924/
[6] Dmitrieva VG, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins after cerebral ischemia. Cell Mol Neurobiology. 2010. — https://pubmed.ncbi.nlm.nih.gov/19633950/
[7] Shadrina MI, et al. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax. Neuroscience Letters. 2001. — https://pubmed.ncbi.nlm.nih.gov/11457573/
[8] Shadrina M, et al. NGF and BDNF gene expression dynamics in rat hippocampus under Semax action. J Mol Neuroscience. 2010. — https://pubmed.ncbi.nlm.nih.gov/19662538/
[10] Kost NV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. 2001. — https://pubmed.ncbi.nlm.nih.gov/11443939/
[12] Volodina MA, et al. Correction of Long-Lasting Negative Effects of Neonatal Isolation Using Semax. Acta Naturae. 2012. — https://pmc.ncbi.nlm.nih.gov/articles/PMC3372995/
[13] Volodina MA, et al. Semax attenuates the influence of neonatal maternal deprivation. Bull Exp Biol Med. 2012. — https://pubmed.ncbi.nlm.nih.gov/22803132/
[15] Kurysheva NI, et al. Semax in the treatment of glaucomatous optic neuropathy. Vestnik Oftalmologii. 2001. — https://pubmed.ncbi.nlm.nih.gov/11569188/
[16] Inozemtseva LS, et al. Antidepressant-like effects of Semax and Melanotan II in chronic unpredictable stress. European Journal of Pharmacology. 2024. — https://pubmed.ncbi.nlm.nih.gov/39442746/
[19] Volodina MA, et al. Effect of Semax on Intracellular Calcium Dynamics in Rat Brain Neurons. Bull Exp Biol Med. 2025. — https://link.springer.com/article/10.1007/s10517-025-06501-z
[20] Tomasello MF, et al. Semax, a Copper Chelator Peptide, Decreases Cu(II)-Catalyzed ROS. Bioinorganic Chemistry and Applications. 2025. — https://pmc.ncbi.nlm.nih.gov/articles/PMC12151629/
[21] Liu et al. Semax targets Oprm1 to promote deubiquitination after spinal cord injury. British Journal of Pharmacology. 2025. — https://pubmed.ncbi.nlm.nih.gov/40692165/

---

A kiln-fired digest of the peer-reviewed Semax record — heptapeptide research indexed from the literature, no clinic behind the shelf.